Cargando…

Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study

INTRODUCTION: Atrial fibrillation (AF) is a worldwide healthcare burden that is associated with the ageing population. Elderly patients with AF with multiple comorbidities usually present with a high risk of thromboembolism and bleeding. Limited prospective data are available from Asian cohorts on t...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yutao, Wang, Yutang, Li, Xiaoying, Shan, Zaoliang, Shi, Xiangmin, Xi, Guorong, Lip, Gregory Y H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942423/
https://www.ncbi.nlm.nih.gov/pubmed/29730624
http://dx.doi.org/10.1136/bmjopen-2017-020191
_version_ 1783321468431499264
author Guo, Yutao
Wang, Yutang
Li, Xiaoying
Shan, Zaoliang
Shi, Xiangmin
Xi, Guorong
Lip, Gregory Y H
author_facet Guo, Yutao
Wang, Yutang
Li, Xiaoying
Shan, Zaoliang
Shi, Xiangmin
Xi, Guorong
Lip, Gregory Y H
author_sort Guo, Yutao
collection PubMed
description INTRODUCTION: Atrial fibrillation (AF) is a worldwide healthcare burden that is associated with the ageing population. Elderly patients with AF with multiple comorbidities usually present with a high risk of thromboembolism and bleeding. Limited prospective data are available from Asian cohorts on the epidemiology and complications of AF. The present prospective cohort study aims to explore contemporary antithrombotic strategies among the elderly Chinese population in the new era of non-vitamin K antagonist oral anticoagulants and to compare the clinical characteristics and outcomes between Chinese and European AF populations. METHODS AND ANALYSIS: The Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry will recruit 5000 patients with AF over 65 years of age in China. AF-related risks, including stroke/systemic thromboembolism and bleeding outcomes, will be assessed. Medical history, risk factors, demographic information and management will be collected at baseline, and clinical events during 1 year follow-up will be recorded. Follow-up will be conducted for at least 1 year and then annually thereafter. As our registry has a common protocol to the European Society of Cardiology EURObservational Research Programme AF general registry programme, preplanned analyses comparing the clinical profiles and outcomes will be performed. The ChiOTEAF registry offers an opportunity to provide a better understanding of the clinical profiles and adverse outcomes of patients with AF in China and allow for comparisons with a contemporary European population. ETHICS AND DISSEMINATION: Ethics approval was granted by the Central Medical Ethic Committee of Chinese PLA General Hospital (approval no S2014-065-01). The (inter)national research presentations, peer-reviewed publications and media coverage of the research will be sued for dissemination of the results.
format Online
Article
Text
id pubmed-5942423
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-59424232018-05-11 Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study Guo, Yutao Wang, Yutang Li, Xiaoying Shan, Zaoliang Shi, Xiangmin Xi, Guorong Lip, Gregory Y H BMJ Open Epidemiology INTRODUCTION: Atrial fibrillation (AF) is a worldwide healthcare burden that is associated with the ageing population. Elderly patients with AF with multiple comorbidities usually present with a high risk of thromboembolism and bleeding. Limited prospective data are available from Asian cohorts on the epidemiology and complications of AF. The present prospective cohort study aims to explore contemporary antithrombotic strategies among the elderly Chinese population in the new era of non-vitamin K antagonist oral anticoagulants and to compare the clinical characteristics and outcomes between Chinese and European AF populations. METHODS AND ANALYSIS: The Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry will recruit 5000 patients with AF over 65 years of age in China. AF-related risks, including stroke/systemic thromboembolism and bleeding outcomes, will be assessed. Medical history, risk factors, demographic information and management will be collected at baseline, and clinical events during 1 year follow-up will be recorded. Follow-up will be conducted for at least 1 year and then annually thereafter. As our registry has a common protocol to the European Society of Cardiology EURObservational Research Programme AF general registry programme, preplanned analyses comparing the clinical profiles and outcomes will be performed. The ChiOTEAF registry offers an opportunity to provide a better understanding of the clinical profiles and adverse outcomes of patients with AF in China and allow for comparisons with a contemporary European population. ETHICS AND DISSEMINATION: Ethics approval was granted by the Central Medical Ethic Committee of Chinese PLA General Hospital (approval no S2014-065-01). The (inter)national research presentations, peer-reviewed publications and media coverage of the research will be sued for dissemination of the results. BMJ Publishing Group 2018-05-05 /pmc/articles/PMC5942423/ /pubmed/29730624 http://dx.doi.org/10.1136/bmjopen-2017-020191 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Epidemiology
Guo, Yutao
Wang, Yutang
Li, Xiaoying
Shan, Zaoliang
Shi, Xiangmin
Xi, Guorong
Lip, Gregory Y H
Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study
title Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study
title_full Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study
title_fullStr Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study
title_full_unstemmed Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study
title_short Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study
title_sort optimal thromboprophylaxis in elderly chinese patients with atrial fibrillation (chioteaf) registry: protocol for a prospective, observational nationwide cohort study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942423/
https://www.ncbi.nlm.nih.gov/pubmed/29730624
http://dx.doi.org/10.1136/bmjopen-2017-020191
work_keys_str_mv AT guoyutao optimalthromboprophylaxisinelderlychinesepatientswithatrialfibrillationchioteafregistryprotocolforaprospectiveobservationalnationwidecohortstudy
AT wangyutang optimalthromboprophylaxisinelderlychinesepatientswithatrialfibrillationchioteafregistryprotocolforaprospectiveobservationalnationwidecohortstudy
AT lixiaoying optimalthromboprophylaxisinelderlychinesepatientswithatrialfibrillationchioteafregistryprotocolforaprospectiveobservationalnationwidecohortstudy
AT shanzaoliang optimalthromboprophylaxisinelderlychinesepatientswithatrialfibrillationchioteafregistryprotocolforaprospectiveobservationalnationwidecohortstudy
AT shixiangmin optimalthromboprophylaxisinelderlychinesepatientswithatrialfibrillationchioteafregistryprotocolforaprospectiveobservationalnationwidecohortstudy
AT xiguorong optimalthromboprophylaxisinelderlychinesepatientswithatrialfibrillationchioteafregistryprotocolforaprospectiveobservationalnationwidecohortstudy
AT lipgregoryyh optimalthromboprophylaxisinelderlychinesepatientswithatrialfibrillationchioteafregistryprotocolforaprospectiveobservationalnationwidecohortstudy